Effects of Immulina TM Supplements With PASC Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

July 29, 2025

Study Completion Date

July 29, 2025

Conditions
Post Acute COVID-19 Syndrome
Interventions
DRUG

Immulina TM

Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.

DIETARY_SUPPLEMENT

Placebo

Placebo is an inert form of cellulose acetate.

Trial Locations (9)

26506

West Virginia University, Morgantown

39216

University of Mississippi Medical Center, Jackson

68198

University of Nebraska Medical Center, Omaha

70112

Louisiana State University, New Orleans

70808

Pennington Biomedical Research Center, Baton Rouge

73104

University of Oklahoma, Oklahoma City

96813

University of Hawaii, Honolulu

04101

MaineHealth, Portland

00935

University of Puerto Rico, San Juan

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

University of Mississippi Medical Center

OTHER